Relief Therapeutics/NeuroRx's Aviptadil Promise In COVID-19-Associated Respiratory Failure
Randomized Trial Results Expected Later This Quarter
Executive Summary
Although top-line efficacy results from a small study in critically ill patients with COVID-19 suggest there are therapeutic benefits associated with Relief Therapeutics/NeuroRx’s RLF-100 (aviptadil), further data are awaited from the results of a randomized clinical trial, expected later this year.
You may also be interested in...
Peptomyc Battles Cancer R&D Conventions
Laura Soucek, one of In Vivo’s 2020 Rising Leaders, is hoping to take Barcelona-based start-up Peptomyc to the next level. The company is nearing the clinic with an inhibitor of the transcription factor Myc, which is involved in the regulation of cellular proliferation, but can also be a driver of cancer.
Pipeline Watch: Ulcerative Colitis, COVID-19 Clinical Trial Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Synairgen Supercharges R&D With $100m Financing
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.
Need a specific report? 1000+ reports available
Buy Reports